Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Holding RARE?
Track your performance easily

Ultragenyx Pharmaceutical (RARE) Cash flow

744 Followers

Ultragenyx Pharmaceutical Cash Flow

RARE's free cash flow for Q3 2024 was $-68.61M. For the 2024 fiscal year, RARE's free cash flow was decreased by $5.01M and operating cash flow was $-67.00M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
$ -418.59M$ -474.81M$ -380.46M$ -338.69M$ -132.22M$ -345.38M
Investing Cash Flow
$ -227.52M$ 168.00M$ -291.65M$ -195.37M$ -179.12M$ -13.04M
Financing Cash Flow
$ 726.66M$ 388.14M$ 501.21M$ 118.51M$ 600.27M$ 679.31M
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
$ 993.02M$ 219.40M$ 137.60M$ 309.54M$ 726.29M$ 436.24M
Income Tax Paid Supplemental Data
------
Interest Paid Supplemental Data
------
Issuance Of Capital Stock
$ 53.30M$ 53.30M--$ 511.21M$ 355.24M
Issuance Of Debt
------
Repayment Of Debt
-----$ 0.00
Free Cash Flow
$ -354.02M$ -521.57M$ -526.59M$ -411.79M$ -176.13M$ -370.21M
Domestic Sales
------
Foreign Sales
------
Currency in USD

Ultragenyx Pharmaceutical Cash Flow

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis